Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT ID: NCT02634606

Last Updated: 2019-02-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-22
• Study Completion Date: 2015-11-13

Brief Summary

Elevated blood cholesterol, and particularly LDL cholesterol, is a risk factor for heart disease. Tocotrienols are naturally-occurring compounds in foods that may have beneficial effects on blood cholesterol. Tocotrienols are members of the vitamin E family, and are found in barley, oats, rye, coconut oil and rice bran oil, but the richest source of tocotrienols is palm oil. Certain of these tocotrienols have been shown to be effective in lowering LDL (or 'bad') cholesterol, with no adverse effects on the HDL (or 'good') cholesterol. The purpose of this study is to determine the effects of a palm-oil derived tocotrienol supplement on blood cholesterol, and particularly LDL cholesterol, in individuals who are taking statins, and have either elevated or normal cholesterol levels. Study subjects will consume a palm-oil derived supplement of tocotrienol for 3 months to determine its effects on LDL cholesterol.

Detailed Description

Both tocotrienols and tocopherols, whose derivatives are in eight different isoforms, are closely related structurally. Tocopherols are generally present in common vegetable oils (i.e. soy, canola). However, tocotrienols are concentrated in cereal grains (ie. oat, barley, and rye, rice bran), with the highest level found in crude palm oil. The development of new cholesterol-lowering agents has been given more and more attention by pharmaceutical companies due to the strong relationship between cholesterol and atherosclerosis. Tocotrienols, especially δ- and γ-tocotrienols, were shown to be effective nutritional agents to treat high cholesterol in recent research programs. In particular, γ-tocotrienol appears to inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase at a posttranscriptional level and there is some evidence that tocopherols antagonize this effect. Therefore, the current study is designed to demonstrate that treatment with a tocotrienol-enriched fraction of palm oil for a three month period will lead to a significant reduction in LDL cholesterol with no effect on HDL cholesterol in patients whose cholesterol level is not adequately controlled in spite of statins. This objective will be achieved utilizing a simple three arm randomized placebo-controlled trial in a total of 99 subjects After acclimation to a step I AHA diet and no supplemental vitamin E in the diet, subjects will be given either a placebo capsule or a tocotrienol (120mg or 240mg) capsule in addition to their statin medications

Conditions

Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Gamma Delta Tocotrienols - Low Dose

33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.

Group Type: ACTIVE_COMPARATOR

Gamma Delta Tocotrienols - Low Dose

Intervention Type: DRUG

250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.

Gamma Delta Tocotrienols - High Dose

33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.

Group Type: ACTIVE_COMPARATOR

Gamma Delta Tocotrienols - High Dose

Intervention Type: DRUG

250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.

Sugar Pill

33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Sugar Pill

Intervention Type: DRUG

250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.

Interventions

Gamma Delta Tocotrienols - Low Dose

250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.

Intervention Type: DRUG

Gamma Delta Tocotrienols - High Dose

250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.

Intervention Type: DRUG

Sugar Pill

250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.

Intervention Type: DRUG

Other Intervention Names

Tocotrienol-enriched Fraction of Palm Oil (TRF); Tocotrienol-enriched Fraction of Palm Oil (TRF); Placebo

Eligibility Criteria

Inclusion Criteria

• Able to read, speak, and understand English
• Male or female, 35-70 years old (inclusive)
• Total Fasting Plasma Cholesterol of >180 mg/dl
• Currently taking statin medications.
• Willing to maintain AHA Step 1 diet for the duration of the study.

Exclusion Criteria

• Any subject who is taking vitamin E supplements or taking any antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols.
• Any subject who is taking cholesterol lowering medications other than statins.
• Any subject who has lost >5% of their body weight during the past 3 months.
• Any subjects with a history of gastrointestinal surgery, diabetes mellitus, or other serious medical condition, such as chronic hepatitis or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as BP >160mmHg, diastolic BP>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.
• Major surgery within 12 weeks prior to subject randomization and/or screening, especially cardiac surgery
• Is currently a smoker who has a therapeutic plan to quit smoking anytime during the study period; or if not a current smoker, has quit smoking within the past 3 months.
• Known HIV positive or known immunocompromised condition (e.g. MV, organ transplantation, treatment with immunosuppressant medications).
• Clinical evidence of current malignancy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia.
• Currently receiving systemic chemotherapy and/or radiotherapy.
• Active bleeding.
• Subject has any disorder (excluding illiteracy or visual impairment) that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
• In the opinion of the study investigator has a risk of non-compliance with study procedures, or cannot read, understand or complete study related materials.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Zhaoping Li

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Zhaoping Li, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

David Heber, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

UCLA Center for Human Nutrition, 900 Veteran Avenue, WH 14-187

Los Angeles, California, United States

Countries

United States

Other Identifiers

TOCO 11-000665

Identifier Type: -

Identifier Source: org_study_id